In short
Non-small cell lung cancer is the most common form of lung cancer, affecting thousands of people worldwide every year. Treatment approaches range from well-established surgical and drug therapies to innovative methods currently being tested in clinical trials, offering hope for better outcomes and improved quality of life.
Key points
- Non-small cell lung cancer accounts for 80-85% of all lung cancer cases and grows more slowly than small cell lung cancer, but is often diagnosed after it has already spread.
- Treatment depends on the stage of the cancer, the patient's overall health, and specific genetic mutations found in the tumor through molecular testing.
- Surgery is the preferred treatment for early-stage cancer, while chemotherapy, radiation, targeted therapy, and immunotherapy are used for more advanced disease.
- Targeted therapies attack specific genetic mutations like EGFR, ALK, ROS1, BRAF, KRAS, RET, and MET, offering more precise treatment with potentially fewer side effects than traditional chemotherapy.
- Immunotherapy drugs called checkpoint inhibitors help the immune system recognize and attack cancer cells by blocking proteins like PD-1 and PD-L1.
- Clinical trials test new treatments and may provide access to cutting-edge therapies, with phases ranging from safety testing (Phase I) to comparison with standard care (Phase III).
- Neoadjuvant therapy, such as nivolumab combined with chemotherapy before surgery, was approved in 2022 based on the CheckMate 816 trial and can improve outcomes for patients with larger tumors.
- Palliative care, which focuses on symptom relief and quality of life, can be given alongside cancer treatment and has been shown to improve both well-being and survival.
Finding the Right Path: Understanding Treatment Goals for Non-Small Cell Lung Cancer
When someone receives a diagnosis of non-small cell lung cancer, one of the first questions that comes to mind is what treatment will involve. The primary goals of treatment depend on many factors, including how far the cancer has spread, the overall health of the patient, and specific characteristics of the cancer cells themselves. For some patients, the aim is to remove the cancer completely through surgery. For others, the focus shifts to controlling the disease, managing symptoms, and maintaining the best possible quality of life for as long as possible.
Treatment decisions are never one-size-fits-all. Medical teams consider the stage of the disease—meaning how large the tumor is and whether it has spread beyond the lungs to other parts of the body. They also look at the patient's age, lung function, and other health conditions that might affect how well someone can tolerate certain therapies. Additionally, modern medicine has made it possible to examine the cancer at a molecular level, identifying specific genetic changes that can guide treatment choices.
There are treatments that have been used for years and are considered standard care, approved by medical societies and backed by extensive research. At the same time, researchers are constantly exploring new therapies through clinical trials. These studies test experimental drugs and innovative approaches that might one day become the new standard. Patients who participate in clinical trials gain access to cutting-edge treatments while contributing to scientific knowledge that could help future patients.
Standard Treatment Options: What Has Been Proven to Work
For patients whose cancer is detected early and has not spread beyond the lung, surgery is often the first line of treatment. During the operation, a surgeon removes the tumor along with a small margin of healthy tissue around it to ensure all cancer cells are eliminated. In some cases, if the cancer has spread more extensively within the lung, part or all of the lung may need to be removed in a procedure called lung resection. Unfortunately, early-stage lung cancer is relatively rare, as many cases are diagnosed after the disease has already advanced.
When surgery is not an option—either because the cancer has spread too far or because the patient's overall health makes surgery too risky—other treatments become the mainstay. Chemotherapy involves using powerful drugs that kill rapidly dividing cells, including cancer cells. These drugs are usually given in cycles, allowing the body time to recover between treatments. Common chemotherapy drugs for non-small cell lung cancer include platinum analogs such as cisplatin and carboplatin, often combined with other agents like pemetrexed or gemcitabine. Chemotherapy can shrink tumors, slow disease progression, and relieve symptoms, but it also comes with side effects such as nausea, hair loss, fatigue, and increased risk of infection.
Radiation therapy uses high-energy beams to destroy cancer cells or shrink tumors. It is particularly useful for patients who cannot undergo surgery or as an additional treatment after surgery to eliminate any remaining cancer cells. Radiation can also be used to relieve symptoms like pain or bleeding caused by tumors pressing on nearby structures. The treatment is carefully planned to target the tumor while minimizing damage to healthy lung tissue and surrounding organs.
In recent years, targeted therapy has become a cornerstone of treatment for many patients with non-small cell lung cancer. These drugs are designed to attack specific genetic mutations or proteins that help cancer cells grow. For example, some tumors have mutations in the EGFR (epidermal growth factor receptor) gene. Drugs called EGFR inhibitors, such as erlotinib, gefitinib, and osimertinib, can block this protein and slow or stop cancer growth. Other targeted therapies work against mutations in genes like ALK (anaplastic lymphoma kinase), ROS1, BRAF, and KRAS. Before starting targeted therapy, doctors perform molecular testing on a sample of the tumor to identify which mutations are present.
Immunotherapy represents another major advance in lung cancer treatment. These drugs help the body's own immune system recognize and attack cancer cells. Cancer cells often hide from the immune system by using proteins like PD-1 or PD-L1 that act as a "brake" on immune responses. Immunotherapy drugs called checkpoint inhibitors—such as nivolumab, pembrolizumab, and atezolizumab—block these proteins, allowing the immune system to attack the tumor more effectively. Immunotherapy can be used alone or in combination with chemotherapy, depending on the stage of the disease and the presence of specific biomarkers.
The duration of treatment varies widely. Chemotherapy is typically given in cycles over several months. Targeted therapies and immunotherapies may be continued for as long as they are working and the patient tolerates them well. Side effects differ depending on the type of treatment. Chemotherapy often causes nausea, fatigue, and hair loss. Targeted therapies can lead to skin rashes, diarrhea, and liver problems. Immunotherapy may cause immune-related side effects, such as inflammation of the lungs, intestines, or other organs, because the treatment activates the immune system broadly.
For patients with advanced disease, treatment is often aimed at controlling the cancer and managing symptoms rather than curing it. This is where palliative care plays a vital role. Palliative care focuses on relieving pain, shortness of breath, and other symptoms to improve quality of life. Studies have shown that patients who receive palliative care alongside standard cancer treatment often experience better quality of life and may even live longer.
Treatment in Clinical Trials: Exploring the Future of Lung Cancer Care
Clinical trials are research studies that test new treatments or new ways of using existing treatments. For patients with non-small cell lung cancer, participating in a clinical trial can provide access to the latest therapies that are not yet available to the general public. These trials are carefully designed to evaluate the safety and effectiveness of new drugs or treatment combinations.
Clinical trials are conducted in phases. Phase I trials focus primarily on safety. Researchers want to know what dose of a new drug is safe and what side effects it causes. These trials usually involve a small number of patients. Phase II trials test whether the treatment works—does it shrink tumors or slow disease progression? These studies involve more patients and provide early evidence of effectiveness. Phase III trials compare the new treatment to the current standard of care, often involving hundreds or even thousands of patients. If a Phase III trial shows that the new treatment is better than or as good as existing options with fewer side effects, it may be approved by regulatory agencies for widespread use.
One area of intense research is the use of neoadjuvant therapy, which means giving treatment before surgery. The goal is to shrink the tumor, making it easier to remove and potentially reducing the risk of the cancer coming back. In 2022, the combination of the immunotherapy drug nivolumab with platinum-based chemotherapy was approved for use before surgery in patients with tumors that are at least 4 centimeters or have spread to nearby lymph nodes. This approval was based on results from the CheckMate 816 trial, which showed that patients who received this combination had better outcomes than those who received chemotherapy alone.
Another promising area of research involves drugs that target specific molecular pathways. For example, RET kinase inhibitors are being tested in patients whose tumors have changes in the RET gene. Similarly, MET tyrosine kinase inhibitors target abnormalities in the MET gene. These drugs are designed to be highly specific, attacking cancer cells while sparing normal cells and potentially causing fewer side effects than traditional chemotherapy.
KRAS inhibitors represent a major breakthrough. The KRAS gene is one of the most commonly mutated genes in lung cancer, but for many years it was considered "undruggable." Recently, drugs like sotorasib and adagrasib have been developed to target a specific mutation called KRAS G12C. Early trial results have shown that these drugs can shrink tumors in patients with this mutation, offering a new treatment option for a group of patients who previously had few choices.
Researchers are also exploring combinations of different types of therapy. For example, some trials are testing whether combining immunotherapy with targeted therapy or with anti-VEGF inhibitors—drugs that block the formation of new blood vessels that feed tumors—can improve outcomes. Other studies are looking at whether adding drugs that target multiple pathways at once can overcome resistance to treatment.
Clinical trials are conducted at major cancer centers and hospitals around the world, including in the United States, Europe, and increasingly in other regions. Eligibility for a trial depends on many factors, including the stage of the cancer, previous treatments received, and the presence of specific genetic mutations. Patients interested in participating in a clinical trial should discuss the option with their oncologist, who can help determine whether a suitable trial is available.
Most common treatment methods
- Surgery
- Removal of the tumor and surrounding healthy tissue, used primarily when the cancer is detected early and has not spread beyond the lung.
- May involve removal of part or all of the lung (lung resection) if the cancer has spread within the lung.
- Chemotherapy
- Uses drugs such as platinum analogs (cisplatin, carboplatin) often combined with pemetrexed or gemcitabine to kill rapidly dividing cancer cells.
- Given in cycles over several months, with side effects including nausea, fatigue, hair loss, and increased infection risk.
- Radiation therapy
- Uses high-energy beams to destroy cancer cells or shrink tumors.
- Can be used for patients who cannot undergo surgery, after surgery to eliminate remaining cells, or to relieve symptoms like pain or bleeding.
- Targeted therapy
- Drugs that attack specific genetic mutations or proteins, such as EGFR inhibitors (erlotinib, gefitinib, osimertinib) for tumors with EGFR mutations.
- Other targets include ALK, ROS1, BRAF, KRAS, RET, and MET gene changes.
- Requires molecular testing to identify which mutations are present in the tumor.
- Immunotherapy
- Checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab) block proteins like PD-1 or PD-L1, allowing the immune system to attack cancer cells.
- Can be used alone or combined with chemotherapy, depending on disease stage and biomarkers.
- Side effects may include immune-related inflammation of organs.
- Neoadjuvant therapy
- Treatment given before surgery to shrink tumors and improve surgical outcomes.
- Nivolumab combined with platinum-based chemotherapy has been approved for use before surgery in patients with tumors 4 cm or larger or with lymph node involvement, based on the CheckMate 816 trial.
- Combined chemoradiation therapy
- Combination of chemotherapy and radiation therapy used for patients with locally advanced disease who are not candidates for surgery.
- Palliative care
- Focuses on relieving symptoms such as pain and shortness of breath to improve quality of life.
- Can be given alongside standard cancer treatment and has been shown to improve outcomes.
